Erda tinib

The urothelial carcinoma cell lines SW780 (FGFR3-BAIP2L1 fusion) and RT4 (FGFR3-TACC3 fusion) were obtained from the American Type Culture Collection (ATCC). Cells were maintained in Dulbecco's Modi ed Eagle Medium (DMEM/F-12, plus glutamine and sodium bicarbonate (Invitrogen, Carlsbad, CA, USA) supplemented with 1% GlutaMax, 1% HEPES, 1% Penicillin/Streptomycin, and 10% Fetal Bovine Serum (Invitrogen), and incubated at 37°C in 5% Carbon Dioxide. BGJ398 was obtained from Novartis (Basel, Switzerland). AZD8931, R428 and erda tinib were purchased from Selleck Chemicals (Houston, TX, USA).

Cell lines, culture and reagents
The urothelial carcinoma cell lines SW780 (FGFR3-BAIP2L1 fusion) and RT4 (FGFR3-TACC3 fusion) were obtained from the American Type Culture Collection (ATCC). Cells were maintained in Dulbecco's Modi ed Eagle Medium (DMEM/F-12, plus glutamine and sodium bicarbonate (Invitrogen, Carlsbad, CA, USA) supplemented with 1% GlutaMax, 1% HEPES, 1% Penicillin/Streptomycin, and 10% Fetal Bovine Serum (Invitrogen), and incubated at 37°C in 5% Carbon Dioxide. BGJ398 was obtained from Novartis (Basel, Switzerland) or from Selleck Chemicals (Houston, TX, USA). AZD8931, erda tinib and TAS-120 were purchased from Selleck Chemicals.

Cell viability was measured using the CellTitre-Glo luminescent cell viability assay (Promega, Madison, WI, USA). Cells were seeded in white 96 well at bottom plates at a density of 1500-5000 cells per well, then treated the following day with drug for 72 hours. Luminescence was measured using a SpectraMax L Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) and compared to DMSO treated cells. BGJ398, Erda tinib, TAS-120, Trametinib and AZD-8931 were all purchased from Selleck Chemicals and dissolved in DMSO.